Interruption of this PD-1/PD-L1 interaction with either anti-PD-1 monoclonal antibody (mAb) or anti-PD-L1 mAb results in activation of anti-tumor immune response (8) (Figure 1A). Here, PDCD1 is linked to neoplasm.